Top

Published in:

01-03-2018 | Clinical Study

The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas

Authors: Te Whiti Rogers, Gurvinder Toor, Katharine Drummond, Craig Love, Kathryn Field, Rebecca Asher, Alpha Tsui, Michael Buckland, Michael Gonzales

Published in: Journal of Neuro-Oncology | Issue 1/2018

Abstract

The classification of central nervous system tumours has more recently been shaped by a focus on molecular pathology rather than histopathology. We re-classified 82 glial tumours according to the molecular-genetic criteria of the 2016 revision of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System. Initial diagnoses and grading were based on the morphological criteria of the 2007 WHO scheme. Because of the impression of an oligodendroglial component on initial histological assessment, each tumour was tested for co-deletion of chromosomes 1p and 19q and mutations of isocitrate dehydrogenase (IDH-1 and 2) genes. Additionally, expression of proteins encoded by alpha-thalassemia X-linked mental retardation (ATRX) and TP53 genes was assessed by immunohistochemistry. We found that all but two tumours could be assigned to a specific category in the 2016 revision. The most common change in diagnosis was from oligoastrocytoma to specifically astrocytoma or oligodendroglioma. Analysis of progression free survival (PFS) for WHO grade II and III tumours showed that the objective criteria of the 2016 revision separated diffuse gliomas into three distinct molecular categories: chromosome 1p/19q co-deleted/IDH mutant, intact 1p/19q/IDH mutant and IDH wild type. No significant difference in PFS was found when comparing IDH mutant grade II and III tumours suggesting that IDH status is more informative than tumour grade. The segregation into distinct molecular sub-types that is achieved by the 2016 revision provides an objective evidence base for managing patients with grade II and III diffuse gliomas based on prognosis.

von Deimling A (eds) (2016) WHO classification of tumours of the central nervous system. IARC, Lyon

Louis DN, Ohgaki H, Wiestler OD, Cavanee WK (eds) (2007) WHO classification of tumours of the central nervous system. IARC, Lyon

Buckner J, Giannini C, Eckel-Passow J, Lachance D, Parney I, Laack N, Jenkins R (2017) Management of diffuse low-grade gliomas in adults: use of molecular diagnostics. Nat Rev Neurol 13:340–351. https://doi.org/10.1038/nrneurol.2017.54 CrossRefPubMed

Wang H, Xu T, Jiang Y, Xu H, Yan Y, Fu D, Chen J (2015) The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia 17:239–255. https://doi.org/10.1016/j.neo.2015.02.002 CrossRefPubMedPubMedCentral

Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599–601. https://doi.org/10.1007/s00401-009-0595-z CrossRefPubMed

Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331:1199–1203. https://doi.org/10.1126/science.1200609 CrossRefPubMedPubMedCentral

Pardo FS, Hsu DW, Zeheb R, Efird JT, Okunieff PG, Malkin DM (2004) Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage. Br J Cancer 91:1678–1686. https://doi.org/10.1038/sj.bjc.6602161 CrossRefPubMedPubMedCentral

Takami H, Yoshida A, Fukushima S, Arita H, Matsushita Y, Nakamura T, Ohno M, Miyakita Y, Shibui S, Narita Y, Ichimura K (2015) Revisiting TP53 mutations and immunohistochemistry: a comparative study in 157 diffuse gliomas. Brain Pathol 25:256–265. https://doi.org/10.1111/bpa.12173 CrossRefPubMed

Gonzales M, Dale S, Susman M, Mills J (2006) Quantitation of chromosome 1p and 19q deletions in glial tumours by interphase FISH on formalin-fixed paraffin-embedded tissue. J Clin Neurosci 13:96–101. https://doi.org/10.1016/j.jocn.2005.06.004 CrossRefPubMed

10.

Gupta R, Flanagan S, Li CC, Lee M, Shivalingham B, Maleki S, Wheeler HR, Buckland ME (2013) Expanding the spectrum of IDH1 mutations in gliomas. Mod Pathol 26:619–625. https://doi.org/10.1038/modpathol.2012.210 CrossRefPubMed

11.

Cai J, Zhang C, Zhang W, Wang G, Yao K, Wang Z, Li G, Qian Z, Li Y, Jiang T, Jiang C (2016) ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. Oncoscience 3:258–265PubMedPubMedCentral

12.

Juratli TA, Kirsch M, Robel K, Soucek S, Geiger K, von Kummer R, Schackert G, Krex D (2012) IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. J Neurooncol 108:403–410. https://doi.org/10.1007/s11060-012-0844-1 CrossRefPubMed

13.

Iuchi T, Namba H, Iwadate Y, Shishikura T, Kageyama H, Nakamura Y, Ohira M, Yamaura A, Osato K, Sakiyama S, Nakagawara A (2002) Identification of the small interstitial deletion at chromosome band 1p34-p35 and its association with poor outcome in oligodendroglial tumors. Genes Chromosomes Cancer 35:170–175. https://doi.org/10.1002/gcc.10080 CrossRefPubMed

14.

Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage CA, Polivka M, Lechapt-Zalcman E, Desenclos C, Meyronet D, Delattre JY, Figarella-Branger D, For Pola Network (2016) Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol 132:625–634. https://doi.org/10.1007/s00401-016-1611-8 CrossRefPubMed

15.

Cimino PJ, Zager M, McFerrin L, Wirsching HG, Bolouri H, Hentschel B, von Deimling A, Jones D, Reifenberger G, Weller M, Holland EC (2017) Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Acta Neuropathol Commun 5:39. https://doi.org/10.1186/s40478-017-0443-7 CrossRefPubMedPubMedCentral

16.

Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, Perry A, Giannini C, Tihan T, Berger MS, Wiemels JL, Bracci PM, Eckel-Passow JE, Lachance DH, Clarke J, Taylor JW, Luks T, Wiencke JK, Jenkins RB, Wrensch MR (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001–1016. https://doi.org/10.1007/s00401-017-1690-1 CrossRefPubMed

17.

Mellai M, Annovazzi L, Senetta R, Dell’Aglio C, Mazzucco M, Cassoni P, Schiffer D (2017) Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status. J Neurooncol 131:213–222. https://doi.org/10.1007/s11060-016-2296-5 CrossRefPubMed

18.

Waitkus MS, Diplas BH, Yan H (2016) Isocitrate dehydrogenase mutations in gliomas. Neuro-Oncology 18(1):16–26. https://doi.org/10.1093/neuonc/nov136 CrossRefPubMed

19.

Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A, Sahm F, Koelsche C, Korshunov A, Olar A, Hartmann C, Reijneveld JC, Wesseling P, Unterberg A, Platten M, Wick W, Herold-Mende C, Aldape K, von Deimling A (2015) IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 129:867–873. https://doi.org/10.1007/s00401-015-1438-8 CrossRefPubMedPubMedCentral

20.

Lasocki A, Tsui A, Tacey MA, Drummond KJ, Field KM, Gaillard F (2014) MRI grading versus histology: predicting survival of World Health Organization grade II–IV astrocytomas. Am J Neuroradiol 36:77–83. https://doi.org/10.3174/ajnr.A4077 CrossRefPubMed

21.

Paldor I, Drummond KJ, Kaye AH (2016) IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: a case-control study. J Clin Neurosci 34:117–120. https://doi.org/10.1016/j.jocn.2016.05.016 CrossRefPubMed

22.

Dong X, Noorbakhsh A, Hirshman BR, Zhou T, Tang JA, Chang DC, Carter BS, Chen CC (2015) Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: a SEER-based analysis. Neuro-Oncol Pract. https://doi.org/10.1093/nop/npv016

23.

Oberheim Bush NA, Chang S (2016) Treatment strategies for low-grade glioma in adults. J Oncol Pract 12:1235–1241. https://doi.org/10.1200/JOP.2016.018622 CrossRefPubMed

24.

Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frenay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W, European Federation of Neurological (2010) Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 17:1124–1133CrossRefPubMed

25.

van den Bent MJ, Snijders TJ, Bromberg JE (2012) Current treatment of low grade gliomas. Memo 5:223–227. https://doi.org/10.1007/s12254-012-0014-3 CrossRefPubMedPubMedCentral

26.

Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM (2017) Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol 19:242–251. https://doi.org/10.1093/neuonc/now176 PubMed

27.

Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15:e395–e403. https://doi.org/10.1016/s1470-2045(14)70011-7 CrossRefPubMed

28.

Zadeh G, Khan OH, Vogelbaum M, Schiff D (2015) Much debated controversies of diffuse low-grade gliomas. Neuro Oncol 17:323–326. https://doi.org/10.1093/neuonc/nou368 CrossRefPubMedPubMedCentral

29.

Rosenthal MA, Drummond KJ, Dally M, Murphy M, Cher L, Ashley D, Thursfield V, Giles GG (2006) Management of glioma in Victoria (1998–2000): retrospective cohort study. Med J Aust 184:270–273PubMed

30.

Gan HK, Rosenthal MA, Cher L, Dally M, Drummond K, Murphy M, Thursfield V (2015) Management of glioblastoma in Victoria, Australia (2006–2008). J Clin Neurosci 22:1462–1466. https://doi.org/10.1016/j.jocn.2015.03.029 CrossRefPubMed

31.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Rhun EL, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W (2017) European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18:e315–e329. https://doi.org/10.1016/s1470-2045(17)30194-8 CrossRefPubMed

32.

Ebrahimi A, Skardelly M, Bonzheim I, Ott I, Muhleisen H, Eckert F, Tabatabai G, Schittenhelm J (2016) ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathol Commun 4:60. https://doi.org/10.1186/s40478-016-0331-6 CrossRefPubMedPubMedCentral

33.

Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133–146. https://doi.org/10.1007/s00401-014-1370-3 CrossRefPubMed

34.

Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451. https://doi.org/10.1007/s00401-013-1156-z CrossRefPubMed

35.

Dubbink HJ, Atmodimedjo PN, Kros JM, French PJ, Sanson M, Idbaih A, Wesseling P, Enting R, Spliet W, Tijssen C, Dinjens WN, Gorlia T, van den Bent MJ (2016) Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol 18:388–400. https://doi.org/10.1093/neuonc/nov182 CrossRefPubMed

36.

Kim Y-H, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Vital A, Mariani L, Stawski R, Watanabe T, De Girolami U, Kleihues P, Ohgaki H (2010) Molecular classification of low-grade diffuse gliomas. Am J Pathol 177(6):2708–2714. https://doi.org/10.2353/ajpath.2010.100680 CrossRefPubMedPubMedCentral

Title: The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas
Authors: Te Whiti Rogers
Gurvinder Toor
Katharine Drummond
Craig Love
Kathryn Field
Rebecca Asher
Alpha Tsui
Michael Buckland
Michael Gonzales
Publication date: 01-03-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2710-7

At a glance: The STEP trials

Springer Medicine

The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis

External validity of two nomograms for predicting distant brain failure after radiosurgery for brain metastases in a bi-institutional independent patient cohort

Pre-operative language ability in patients with presumed low-grade glioma

Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis

SNF5 as a prognostic factor in skull base chordoma

Practice patterns and survival outcomes of intracranial germinoma: an analysis of the National Cancer Database